Nischalan Pillay

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7458210/publications.pdf

Version: 2024-02-01

47 papers	3,510 citations	218592 26 h-index	214721 47 g-index
55 all docs	55 docs citations	55 times ranked	5322 citing authors

#	Article	IF	Citations
1	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. European Journal of Cancer, 2022, 162, 221-236.	1.3	22
2	Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA. Nature, 2022, 602, 510-517.	13.7	60
3	Overlapping morphological, immunohistochemical and genetic features of superficial CD34-positive fibroblastic tumor and PRDM10-rearranged soft tissue tumor. Modern Pathology, 2022, 35, 767-776.	2.9	14
4	Unravelling undifferentiated soft tissue sarcomas: insights from genomics. Histopathology, 2022, 80, 109-121.	1.6	3
5	An overview of mutational and copy number signatures in human cancer. Journal of Pathology, 2022, 257, 454-465.	2.1	12
6	Leveraging single cell sequencing to unravel intraâ€tumour heterogeneity and tumour evolution in human cancers. Journal of Pathology, 2022, , .	2.1	6
7	Recent Advances in Pathology: the 2022 Annual Review Issue of The Journal of Pathology. Journal of Pathology, 2022, 257, 379-382.	2.1	2
8	Signatures of copy number alterations in human cancer. Nature, 2022, 606, 984-991.	13.7	154
9	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. Nature Communications, 2021, 12, 117.	5.8	34
10	<scp>DNA</scp> methylationâ€based profiling of bone and soft tissue tumours: a validation study of the â€˜<scp>DKFZ</scp> Sarcoma Classifierâ€™. Journal of Pathology: Clinical Research, 2021, 7, 350-360.	1.3	25
11	Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms. Endocrine-Related Cancer, 2021, 28, 631-644.	1.6	8
12	Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma. Nature Communications, 2021, 12, 7064.	5.8	19
13	Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma. Journal of Pathology: Clinical Research, 2020, 6, 113-123.	1.3	39
14	The genomics of undifferentiated sarcoma of soft tissue: Progress, challenges and opportunities. Seminars in Cancer Biology, 2020, 61, 42-55.	4.3	33
15	<scp>H3K27me3</scp> expression and methylation status in histological variants of malignant peripheral nerve sheath tumours. Journal of Pathology, 2020, 252, 151-164.	2.1	20
16	Drivers underpinning the malignant transformation of giant cell tumour of bone. Journal of Pathology, 2020, 252, 433-440.	2.1	21
17	Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death. Cancer Research, 2020, 80, 4540-4551.	0.4	33
18	Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. Journal of Pathology: Clinical Research, 2020, 6, 297-307.	1.3	20

#	Article	IF	Citations
19	Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs. Genes, 2020, 11, 387.	1.0	16
20	Undifferentiated pleomorphic sarcomas with PRDM10 fusions have a distinct gene expression profile. Journal of Pathology, 2019, 249, 425-434.	2.1	23
21	Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by FN1 gene rearrangement. Modern Pathology, 2019, 32, 1762-1771.	2.9	67
22	CM-Path Molecular Diagnostics Forumâ€"consensus statement on the development and implementation of molecular diagnostic tests in the United Kingdom. British Journal of Cancer, 2019, 121, 738-743.	2.9	2
23	Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. Cancer Cell, 2019, 35, 441-456.e8.	7.7	82
24	FOS Expression in Osteoid Osteoma and Osteoblastoma. American Journal of Surgical Pathology, 2019, 43, 1661-1667.	2.1	50
25	PRDM10-rearranged Soft Tissue Tumor. American Journal of Surgical Pathology, 2019, 43, 504-513.	2.1	35
26	Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts. Oncotarget, 2018, 9, 3946-3955.	0.8	35
27	Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors. Science, 2018, 361, .	6.0	121
28	Recurrent rearrangements of FOS and FOSB define osteoblastoma. Nature Communications, 2018, 9, 2150.	5.8	106
29	Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma. Nature Communications, 2017, 8, 15936.	5.8	179
30	Molecular testing of sarcomas. Diagnostic Histopathology, 2017, 23, 431-441.	0.2	0
31	The driver landscape of sporadic chordoma. Nature Communications, 2017, 8, 890.	5.8	115
32	Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection. Cancer Medicine, 2017, 6, 2194-2202.	1.3	26
33	3-methylcytosine in cancer: an underappreciated methyl lesion?. Epigenomics, 2016, 8, 451-454.	1.0	13
34	EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. Journal of Pathology, 2016, 239, 320-334.	2.1	73
35	Mutational signatures of ionizing radiation in second malignancies. Nature Communications, 2016, 7, 12605.	5.8	214
36	Clinical outcome in patients with peripherallyâ€sited atypical lipomatous tumours and dedifferentiated liposarcoma. Journal of Pathology: Clinical Research, 2015, 1, 106-112.	1.3	9

#	Article	IF	Citations
37	Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclastâ€rich mimics. Journal of Pathology: Clinical Research, 2015, 1, 113-123.	1.3	135
38	GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. Modern Pathology, 2015, 28, 1336-1342.	2.9	47
39	Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neoâ€adjuvant chemotherapy. Cancer Medicine, 2014, 3, 980-987.	1.3	57
40	Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nature Genetics, 2014, 46, 376-379.	9.4	269
41	Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nature Genetics, 2013, 45, 923-926.	9.4	180
42	The G-Proteinâ€“Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis. Clinical Cancer Research, 2013, 19, 5740-5748.	3.2	22
43	Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nature Genetics, 2013, 45, 1479-1482.	9.4	667
44	An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. Journal of Pathology, 2012, 228, 274-285.	2.1	83
45	A common single-nucleotide variant in T is strongly associated with chordoma. Nature Genetics, 2012, 44, 1185-1187.	9.4	112
46	P63 does not regulate brachyury expression in human chordomas and osteosarcomas. Histopathology, 2011, 59, 1025-1027.	1.6	2
47	Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functionalâ€based study. Journal of Pathology, 2011, 223, 327-335.	2.1	174